Last reviewed · How we verify
VARIVAX® PE34 Process
VARIVAX PE34 Process is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox and herpes zoster infection.
VARIVAX PE34 Process is a live attenuated varicella-zoster virus vaccine that stimulates immune response to prevent chickenpox and herpes zoster infection. Used for Prevention of varicella (chickenpox), Prevention of herpes zoster (shingles).
At a glance
| Generic name | VARIVAX® PE34 Process |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus (VZV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains a weakened strain of varicella-zoster virus (Oka strain) that replicates in host cells sufficiently to trigger both cellular and humoral immune responses without causing clinical disease. This generates protective antibodies and cell-mediated immunity against the virus, reducing the risk of primary varicella infection and subsequent reactivation as herpes zoster.
Approved indications
- Prevention of varicella (chickenpox)
- Prevention of herpes zoster (shingles)
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |